Deucravacitinib
Sign in to save this workspacePrimary targets: TYK2 · FDA status: FDA Approved
Selectivity scorecard
KISS
98.99
Gini
0.718
CATDS
0.030
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Deucravacitinib. Strongest target: C_MET at 97.9% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | C_MET | 97.9% | 2.1% |
| 2 | FGFR3 | 93.3% | 6.7% |
| 3 | FGFR2 | 92.5% | 7.5% |
| 4 | FGFR4 | 92.0% | 8.0% |
| 5 | FGFR1 | 85.1% | 14.9% |
| 6 | EIF2AK2 | 83.2% | 16.8% |
| 7 | GSK3B | 75.0% | 25.0% |
| 8 | FLT4_VEGFR3 | 66.8% | 33.2% |
| 9 | HPK1_MAP4K1 | 64.0% | 36.0% |
| 10 | FLT1_VEGFR1 | 61.9% | 38.1% |
| 11 | BMPR2 | 60.8% | 39.2% |
| 12 | LCK | 56.7% | 43.3% |
| 13 | LYN | 49.8% | 50.2% |
| 14 | TNIK | 49.1% | 50.9% |
| 15 | FMS | 46.0% | 54.0% |
| 16 | RET | 45.5% | 54.5% |
| 17 | C_KIT | 45.4% | 54.6% |
| 18 | DDR1 | 44.8% | 55.2% |
| 19 | TYRO3_SKY | 42.0% | 58.0% |
| 20 | ABL1 | 39.7% | 60.3% |
Selectivity landscape
Where Deucravacitinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Deucravacitinib.
Annotations
Sign in to read and post annotations.
Loading…